Fc γ -receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Zimmermann, Heiner ^a   Weiland, Theresa ^b   Nourse, Jamie P ^c   Gandhi, Maher K ^c   Reinke, Petra ^b   Neuhaus, Ruth ^b   Karbasiyan, Mohsen ^b   Gärtner, Barbara ^d   Anagnostopoulos, Ioannis ^b   Riess, Hanno ^b   Trappe, Ralf U ^a,b   Oertel, Stephan ^e  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d SAARLAND UNIVERSITY   (Germany)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FC RECEPTOR; FCGR3A PROTEIN, HUMAN; MONOCLONAL ANTIBODY; RITUXIMAB;

ADOLESCENT; ADULT; AGED; ALLELE; CASE CONTROL STUDY; CLINICAL TRIAL; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; IMMUNOCOMPROMISED PATIENT; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLELES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; POLYMORPHISM, GENETIC; RECEPTORS, IGG; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898680944     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/264723     Document Type: Article

References (29)

1. Penn I., Hammond W., Brettschneider L., Starzl T. E., Malignant lymphomas in transplantation patients. Transplantation Proceedings 1969 1 1 106 112 2-s2.0-0014476231
2. Swerdlow S. H., Webber S. A., Chadburn A., Ferry J. A., Swerdlow S. H., Campo E., Harris N. L., Jaffe E. S., Pileri S. A., Stein H., Post-transplant lymphoproliferative disorders. WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues 2008 4th Lyon, France International Agency for Research on Cancer 343 350
3. Oertel S. H. K., Verschuuren E., Reinke P., Zeidler K., Papp-Váry M., Babel N., Trappe R. U., Jonas S., Hummel M., Anagnostopoulos I., Dörken B., Riess H. B., Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). American Journal of Transplantation 2005 5 12 2901 2906 2-s2.0-33644827381 10.1111/j.1600-6143.2005. 01098.x
4. Choquet S., Leblond V., Herbrecht R., Socié G., Stoppa A., Vandenberghe P., Fischer A., Morschhauser F., Salles G., Feremans W., Vilmer E., Peraldi M., Lang P., Lebranchu Y., Oksenhendler E., Garnier J. L., Lamy T., Jaccard A., Ferrant A., Offner F., Hermine O., Moreau A., Fafi-Kremer S., Morand P., Chatenoud L., Berriot-Varoqueaux N., Bergougnoux L., Milpied N., Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006 107 8 3053 3057 2-s2.0-33645740570 10.1182/blood-2005-01-0377
5. González-Barca E., Domingo-Domenech E., Capote F. J., Gómez-Codina J., Salar A., Bauen A., Ribera J., López A., Briones J., Muñoz A., Encuentra M., De Sevilla A. F., Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 2007 92 11 1489 1494 2-s2.0-36348943532 10.3324/haematol.11360
6. Trappe R., Oertel S., Leblond V., Mollee P., Sender M., Reinke P., Neuhaus R., Lehmkuhl H., Horst H. A., Salles G., Morschhauser F., Jaccard A., Lamy T., Leithäuser M., Zimmermann H., Anagnostopoulos I., Raphael M., Riess H., Choquet S., Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. The Lancet Oncology 2012 13 2 196 206 2-s2.0-84856412562 10.1016/S1470-2045(11) 70300-X
7. Cartron G., Trappe R. U., Solal-Céligny P., Hallek M., Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clinical Cancer Research 2011 17 1 19 30 2-s2.0-78751524881 10.1158/1078-0432.CCR-10-1292
8. Byrd J. C., Kitada S., Flinn I. W., Aron J. L., Pearson M., Lucas D., Reed J. C., The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002 99 3 1038 1043 2-s2.0-0036464611 10.1182/blood.V99.3.1038
9. Harjunpää A., Junnikkala S., Meri S., Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scandinavian Journal of Immunology 2000 51 6 634 641 2-s2.0-0034091481 10.1046/j.1365-3083.2000.00745.x
10. Clynes R. A., Towers T. L., Presta L. G., Ravetch J. V., Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Medicine 2000 6 4 443 446 2-s2.0-0034076307 10.1038/74704
11. Koene H. R., Kleijer M., Algra J., Roos D., Von Dem Borne A. E. G. K., De Haas M., Fc γ RIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FC γ RIIIa, independently of the FC γ RIIIa-48L/R/H phenotype. Blood 1997 90 3 1109 1114 2-s2.0-0030611643
12. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., Watier H., Thibault G., Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Research 2004 64 13 4664 4669 2-s2.0-3042743884 10.1158/0008-5472.CAN-03-2862
13. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., Watier H., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc γ rIIIa gene. Blood 2002 99 3 754 758 2-s2.0-0036464719 10.1182/blood.V99.3.754
14. Weng W.-K., Levy R., Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal of Clinical Oncology 2003 21 21 3940 3947 2-s2.0-0642373290 10.1200/JCO.2003.05.013
15. Persky D. O., Dornan D., Goldman B. H., Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 2012 97 6 937 942 10.3324/haematol.2011.050419
16. Ghesquières H., Cartron G., Seymour J. F., Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood 2012 120 2650 2657 10.1182/blood-2012-05-431825
17. Ahlgrimm M., Pfreundschuh M., Kreuz M., Regitz E., Preuss K., Bittenbring J., The impact of Fc- γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. Blood 2011 118 17 4657 4662 2-s2.0-80055101171 10.1182/blood-2011-04-346411
18. Sasaki M., Terasaki P. I., Silberman H., Berne T., Antibody-dependent cell-mediated cytotoxicity tests for immunosuppression monitoring of transplant patients. Transplantation 1979 27 4 246 249 2-s2.0-0018757915
19. Ten Berge R. J., Schellekens P. T., Surachno S., The influence of therapy with azathioprine and prednisone on the immune system of kidney transplant recipients. Clinical Immunology and Immunopathology 1981 21 1 20 32 2-s2.0-0019452990
20. Prince H. E., Ettenger R. B., Dorey F. J., Azathioprine suppression of natural killer activity and antibody-dependent cellular cytotoxicity in renal transplant recipients. Journal of Clinical Immunology 1984 4 4 312 318 2-s2.0-0021637716
21. Müller C., Schernthaner G., Kovarik J., Natural killer cell activity and antibody-dependent cellular cytotoxicity in patients under various immunosuppressive regimens. Clinical Immunology and Immunopathology 1987 44 1 12 19 2-s2.0-0023267321
22. Wasik M., Gorski A., Stepien-Sopniewska B., Lagodzinski Z., Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. Transplantation 1991 51 1 268 270 2-s2.0-0025969985
23. Eissens D. N., Van Der Meer A., Van Cranenbroek B., Preijers F. W. M. B., Joosten I., Rapamycin and MPA, but not CsA, impair human NK Cell cytotoxicity due to differential effects on NK cell phenotype. American Journal of Transplantation 2010 10 9 1981 1990 2-s2.0-77956167822 10.1111/j.1600-6143.2010. 03242.x
24. Kim T.-J., Kim N., Kang H. J., Kim E.-O., Kim S. T., Ahn H. S., Bluestone J. A., Lee K., FK506 causes cellular and functional defects in human natural killer cells. Journal of Leukocyte Biology 2010 88 6 1089 1097 2-s2.0-78649759743 10.1189/jlb.0310148
25. Nourse J. P., Lea R., Crooks P., Wright G., Tran H., Catalano J., Brighton T., Grigg A., Marlton P., Gandhi M. K., The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms. Blood Coagulation and Fibrinolysis 2012 23 1 45 50 2-s2.0-84855203741 10.1097/MBC.0b013e32834d7ce3
26. Keane C., Nourse J. P., Crooks P., Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. Internal Medicine Journal 2012 42 10 1113 1119 10.1111/j.1445-5994. 2011.02587.x
27. Dall'Ozzo S., Andres C., Bardos P., Watier H., Thibault G., Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR. Journal of Immunological Methods 2003 277 1-2 185 192 2-s2.0-0037870481 10.1016/S0022-1759(03)00123-6
28. Stern M., Opelz G., Döhler B., Hess C., Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. Blood 2010 115 19 3960 3965 2-s2.0-77952993021 10.1182/blood-2009-10-250134
29. Mössner E., Brünker P., Moser S., Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010 115 4393 4402 10.1182/blood-2009-06-225979